Liver fibrosis in the course of metabolic dysfunction-associated steatohepatitis (MASH) could be significantly reduced using CAR T-cells generated in vivo. Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental cell therapy that eliminates only one type of liver cell, the stellate cells that express fibroblast activation protein alpha (FAP). This strategy not only reduced fibrosis but also reversed liver damage. Read More

Intratumoral regulatory T cells (Tregs) suppress antitumor immunity and are linked to poor prognosis across many cancers. These tumor-infiltrating Tregs express high levels of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), making them attractive targets for immunotherapy. However, systemic Treg depletion carries the risk of severe autoimmune toxicity. Read More

Boehringer Ingelheim International GmbH and Simcere Pharmaceutical Group Ltd. have entered into a license and collaboration agreement to develop SIM-0709 for the treatment of inflammatory bowel disease. Read More

Mair Therapeutics BV has established a scientific collaboration with Radboud University to accelerate the discovery of small-molecule agonists of TMEM175, a lysosomal ion channel genetically linked to Parkinson’s disease. Read More

A University of Sydney patent details new cyclic peptides acting as coagulation factor XIa inhibitors reported to be useful for the treatment of thrombosis. Read More

Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in this disease. Read More

Programmed death-ligand 1 (PD-L1) is a crucial immune checkpoint ligand that inhibits antitumor immunity by engaging PD-1 on T cells, and checkpoint blockade has become a pillar of anticancer therapy. However, many patients show limited treatment responses. Read More

Starkage Therapeutics SAS has established a research collaboration with Gustave Roussy to characterize cellular senescence induced by standard-of-care treatments in a series of digestive cancers. Read More

Breast cancer is the most frequently diagnosed malignancy worldwide. Inhibiting PARP-mediated DNA repair has emerged as a promising anticancer strategy, with PARP inhibitors (PARPis) demonstrating clinical efficacy particularly in tumors with defective homologous recombination repair, such as BRCA-deficient cancers. Read More

The University of Kansas has synthesized TNF-α (ARE sequence)/ELAV-like protein 1 (HuR) interaction inhibitors. They are reported to be useful for the treatment of cancer, kidney fibrosis, liver fibrosis, pulmonary fibrosis and myocardial fibrosis. Read More

Gwangju Institute of Science & Technology, National Cancer Center of Korea and Seoul National University have jointly divulged new PreS1 (hepatitis B virus, HBV) derivatives for the treatment of HBV infection. Read More

Akari Therapeutics plc has unveiled a new pipeline candidate, AKTX-102, an antibody-drug conjugate (ADC) directed against CEACAM5, a novel target highly relevant in gastrointestinal and lung cancers. Read More

Novo Nordisk A/S has disclosed GLP-1 polypeptide analogues acting as glucagon-like peptide-1 receptor (GLP-1R) agonists. As such, they are reported to be useful for the treatment of obesity and diabetes. Read More

Suzhou Raymon Pharmaceuticals Co. Ltd. has identified nitric oxide (NO) donor-containing compounds reported to be useful for the treatment of glaucoma, age-related macular degeneration, diabetic retinopathy, cataract, uveitis, keratitis and ocular hypertension. Read More

Acute inflammation is a physiological and host defense response to cardiac injury after suffering myocardial infarction (MI), which programmes cardiac repair and wound healing. Leukocyte-mediated innate inflammatory response is crucial to clear ischemic injury during MI; whilst macrophages produce specialized pro-resolving mediators such as maresin 1, the therapeutic potential of exogenous maresin 1 in cardiac repair is not clear. Read More